Lhotse Bio Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer and fibrosis, among others.
Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others.
Bayer AG’s diacylglycerol kinase ζ (DGK-ζ) inhibitor BAY-2965501 is being developed as a first-in-class cancer immunotherapy candidate. The company recently presented preclinical data on the compound, which supported advancement of the candidate into clinical testing, with a first-in-human phase I study in solid tumors underway (NCT05614102).
Osteosarcoma (OS) is an aggressive cancer type, with frequent metastasis seen in the lungs, and for which two-thirds of metastatic patients fail to achieve durable responses and die due to the disease.
Researchers from Byondis BV and Sanquin Bloedvoorziening have published preclinical data on a new signal-regulatory protein α (SIRPα)-directed antibody, BYON-4228.
A new study has discovered a promising approach to improve the efficacy of adoptive cell therapies for cancer. The research, published in Molecular Therapy: Nucleic Acids, describes the development of novel Fas-TNFR chimeras acting as decoys for the Fas ligand and preventing it from binding to its natural receptor on the surface of chimeric antigen receptor (CAR) T cells.
Research at Pathios Therapeutics Ltd. has led to the identification of tricyclic psychosine receptor (GPR65) antagonists reported to be useful for the treatment of cancer, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease and autoimmune diseases.
A recent Glaxosmithlline Intellectual Property (No 4) Ltd. and Ideaya Biosciences Inc. patent describes the development of thiadiazolyl derivatives acting as DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
RSS
